Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 48

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 48
---
.8 | % |
| S. Michael Rothenberg (14)                                                |     |                           |     12,400 |     |            |    * |   |
| Jake Simson, Ph.D. (15)                                                   |     |                           |     47,600 |     |            |    * |   |
| Rehan Verjee (16)                                                         |     |                           |    115,067 |     |            |    * |   |
| All current directors and executive officers as a group (12 persons) (17) |     |                           |  8,431,622 |     |            | 15.2 | % |

31

| * | Less than 1%. |

| (1) | Based on information contained in the Schedule 13D/A filed with the SEC on March 31, 2025 by entities affiliated with RA Capital. Consists of (i) 8,697,956 shares of our Common Stock held directly by RA Capital Healthcare Fund, L.P. (the “Fund”); (ii) 442,721 shares of our Common Stock held by a separately managed account (the “Account”); (iii) 1,496,613 shares of our Common Stock held by RA Capital Nexus Fund, L.P. (the “Nexus Fund”); and (iv) 47,600 shares of our Common Stock underlying stock options exercisable within 60 days of March 31, 2025 held by Jake Simson, a member of our Board, for the benefit of RA Capital Management, L.P. (“RA Capital”). The total amount of shares beneficially owned does not include any shares of our Common Stock underlying pre-funded warrants described below. The Fund holds pre-funded warrants to purchase 1,538,457 shares of our Common Stock and pre-funded warrants issued in connection with an exchange agreement to purchase 1,000,000 shares of our Common Stock. All of the pre-funded warrants contain a provision which precludes exercise of the warrants to the extent that, following exercise, the Fund, together with its affiliates and other attribution parties, would beneficially own more than 19.99% of our Common Stock outstanding. The Fund is currently prohibited from exercising any of the pre-funded warrants by virtue of such beneficial ownership blocker. RA Capital Healthcare Fund GP, LLC is the general partner of the Fund, and RA Capital Nexus Fund GP, LLC is the general partner of the Nexus Fund. The general partner of RA Capital is